• New Study Suggests Xarelto May Double Risk of Gastrointestinal Bleeding
  • July 14, 2015
  • Law Firm: Waters Kraus LLP - Dallas Office
  • The British Medical Journal has recently published results from a new study indicating that Xarelto, as compared to the generic version of warfarin, may double the risk for gastrointestinal bleeding.

    British Medical Journal Study of Xarelto Reviews 46,000 Patients

    Xarelto has been described by its manufacturer as a prescription anticoagulant, or blood thinner, that is better than warfarin to reduce the likelihood of blood clots in patients receiving knee or hip replacements and for those experiencing Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT). The drug has been wildly successful in the United States - prescribed more than 11 million times.

    For many, however, the drug has been used with disastrous results. When a patient using Xarelto experiences internal bleeding, there is no antidote available to stop the bleeding. Xarelto use has caused many serious injuries and deaths, leading to many state and federal Xarelto lawsuits.

    The British Medical Journal reportedly has recently published a new study concerning the risk that Xarelto may cause gastrointestinal bleeding. Researchers reviewed records of more than 46,000 patients treated with anticoagulants between 2010 and 2012 to explore Xarelto’s overall drug safety. The scientists concluded that they could not rule out previous study findings suggesting that rivaroxaban (Xarelto’s generic equivalent) may carry a risk of gastrointestinal bleeding that is more than two times higher than that of warfarin.